Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;135(8):2648-2650.
doi: 10.1002/lary.32099. Epub 2025 Mar 21.

Does Dupilumab Improve Sinonasal Outcomes in AERD Patients?

Heli Majeethia  1 , Zain Mehdi  1 , Andrew P Lane  2 , Masayoshi Takashima  1 , Omar G Ahmed  1
Affiliations
Review

Does Dupilumab Improve Sinonasal Outcomes in AERD Patients?

Heli Majeethia et al. Laryngoscope. 2025 Aug.

Abstract

This Best Practice review synthesizes evidence from five key clinical trials to evaluate whether dupilumab improves sinonasal outcomes in AERD patients who have undergone prior endoscopic sinus surgery.

Keywords: adult rhinology; allergy/rhinology; clinical; head and neck; immunotherapy; nose and paranasal sinuses.

PubMed Disclaimer

References

    1. K. M. Buchheit, A. Sohail, J. Hacker, et al., “Rapid and Sustained Effect of Dupilumab on Clinical and Mechanistic Outcomes in Aspirin‐Exacerbated Respiratory Disease,” Journal of Allergy and Clinical Immunology 150, no. 2 (2022): 415–424, https://doi.org/10.1016/j.jaci.2022.04.007.
    1. S. S. Mustafa, K. Vadamalai, B. Scott, and A. Ramsey, “Dupilumab as Add‐On Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease,” American Journal of Rhinology & Allergy 35, no. 3 (2021): 399–407, https://doi.org/10.1177/1945892420961969.
    1. C. Bachert, J. K. Han, M. Desrosiers, et al., “Efficacy and Safety of Dupilumab in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): Results From Two Multicentre, Randomised, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Trials,” Lancet 394, no. 10209 (2019): 1638–1650, https://doi.org/10.1016/S0140‐6736(19)31881‐1; 2019 Sep 19.
    1. Erratum in: Lancet. 2019 Nov 2;394(10209):1618, https://doi.org/10.1016/S0140‐6736(19)32218‐4.
    1. T. M. Laidlaw, J. Mullol, C. Fan, et al., “Dupilumab Improves Nasal Polyp Burden and Asthma Control in Patients With CRSwNP and AERD,” Journal of Allergy and Clinical Immunology. In Practice 7, no. 7 (2019): 2462–2465.e1, https://doi.org/10.1016/j.jaip.2019.03.044.

Substances

LinkOut - more resources